Transgene SA

About: Transgene SA is a company organization based out in Illkirch-Graffenstaden, France. It is known for research contribution in the topics: Antigen & Genetic enhancement. The organization has 377 authors who have published 296 publications receiving 12537 citations.

[In vitro and in vivo inhibition of HIV1 replication by retroviral transfer of interferon alpha, beta, or gamma genes: application to gene therapy of AIDS].

Abstract: Somatic gene therapy is defined as the transfer of a heterologous gene into an organism for the purpose of correcting a genetic defect or providing a new therapeutic function to the target cell and thus inducing a cure or improving associated symptoms. While encouraging results have been generated by recent clinical evaluation of combination of anti-viral drugs, Aids still constitute an obvious candidate among the infectious diseases which might be treated by gene therapy. We have therefore chosen to develop and evaluate a gene therapy strategy based on the transfer into human target cells of HIV1-inducible interferon (IFN) alpha, beta or gamma genes. In a preliminary study, myeloid U937 cell lines transfected with expression vectors containing the IFN alpha, beta or gamma genes under the control of the long terminal repeat (LTR) sequences of HIV1 were shown to be strongly resistant against an in vitro and in vivo (in HIV1 challenged SCID mice model) HIV1 infection. This cellular resistance was correlated with a strong induction of transgenic IFN synthesis and for IFN gamma, with a defect of HIV particles maturation. Secondly, construction and production of high titer retroviral vectors containing Tat-inducible IFN genes allowed efficient transduction of lymphoid cell lines and human primary lymphocytes. These transduced cells were shown to be highly resistant against laboratory and primary HIV isolates. Taken together, our in vitro and in vivo results suggest that HIV1 inducible IFN gene therapy can be beneficial to HIV-infected individuals provided the fact that methods are developed that allow the efficient transduction of human hematopoietic stem cells.

Immunologie et cancer. 1re partie: réponse immunitaire antitumorale

Abstract: Le developpement d’une tumeur au sein d’un organisme est etroitement lie a son systeme immunitaire. Il est clairement etabli qu’il existe un processus d’immunosurveillance qui protege l’hote de la mise en place d’un foyer tumoral. Cependant, il est egalement admis que le systeme immunitaire facilite la progression tumorale, notamment en faconnant le phenotype immunogenique de la tumeur au cours de son developpement. Le systeme immunitaire joue donc un double role dans les relations complexes existantes entre l’hote et la tumeur. L’objet de cette revue est de faire le point sur ces differentes interactions en detaillant les acteurs du systeme immunitaire impliques dans la mise en place d’une reponse immunitaire antitumorale.

Cancer vaccines: challenges and outlook in the field.

Abstract: Therapeutic vaccination against cancer-associated antigens represents an attractive option for cancer therapy in view of its efficacy, the possibility of long-lasting immunity against the cancer, and safety profile. Nevertheless, it is now recognized that the same vaccination strategies used for prophylactic vaccinations against infectious diseases, cannot necessarily be used for therapeutic cancer vaccination. Cancer patients are usually immunosuppressed and most cancer-associated antigens are 'self-antigens', making it a significant challenge to vaccinate patients against a cancer-associated antigen. Various immunostimulation techniques are under investigation in an effort to bolster patients' immune systems and to overcome immune tolerance to self antigens. Strategies to stimulate antigen presentation, T-cell reactivity and innate immune activity are under investigation. Several clinical trials have been conducted to evaluate therapeutic cancer vaccines in patients, and attractive protocols, including those that combine the stimulation of specific T-cells and chemotherapy, or strategies to block immune regulation, are beginning to show some success. This feature review considers strategies for the development of effective therapeutic cancer vaccines, and highlights select vaccines that have already entered the clinic.

Device for the administration of a composition in a conduit of a human or animal body

Abstract: The instrument incorporates metal, plastic or mineral perforators or cutters designed to make blind holes in the wall of a duct and a distributor for contacting a medicinal compound with the holes. The cutters or perforators can be extended radially relative to the axis of the instrument, e.g. by means of an inflatable chamber. The substance is distributed through a chamber with radial orifices.